clinical trial · NCT02992964
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
The Hospital for Sick Children·phase2·terminated·n = 11
Refractory or Recurrent Hypermutated MalignanciesBiallelic Mismatch Repair Deficiency (bMMRD) Positive PatientsNivolumab
brief summary
This is an open-label, single arm, multi-center, pilot study of Nivolumab in pediatric patients with recurrent or refractory hypermutant malignancies aged 12 months to 18 years of age. This study is to assess clinical and radiological benefits of treatment with Nivolumab in children with hypermutated cancers, including those with bMMRD syndrome. It is our expectation that patients with bMMRD syndrome will account for the majority of patients enrolled on this study.
started
May 15, 2017
primary completion
Nov 20, 2023
completion
Nov 20, 2023
last updated
Nov 5, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol